Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

General Mills

Kraft Heinz

Mondelez

Northrop Grumman

Verizon

Earnings Distortion Analysis Reveals Opportunity In Defensive Sectors

First Trust Dow Jones Internet Index Fund

iShares U.S. Pharmaceuticals ETF

Merck

VanEck Vectors Pharmaceutical ETF

iShares MSCI USA Quality Factor ETF

Invesco S&P 500 Low Volatility ETF

SPDR S&P 500 ETF Trust

iShares Edge MSCI Min Vol USA ETF

SPDR S&P Biotech ETF

Utilities Select Sector SPDR Fund

Health Care Select Sector SPDR Fund

SPDR S&P Pharmaceuticals ETF

Another bout of sector rotation seems to be underway as investors shed defensive holdings for more aggressive positions.

Quality Play With Pharma ETFs

Johnson & Johnson Chief Executive Officer Alex Gorsky has declined to appear at a U.S. congressional hearing set for Tuesday on the safety of the company's Baby Powder and other talc-based cosmetics.

J&J CEO spurns US congressional hearing on carcinogens in talc products

J&J CEO Gorsky spurns U.S. congressional hearing on carcinogens in talc products

It seems that Johnson & Johnson (NYSE: JNJ) has finally started shaking off those heavy legal headwinds.

Johnson & Johnson Emerging Out Of A Dark Place

J&J's (JNJ) initial data on CAR-T therapy candidate JNJ-68284528 from an early-stage study shows promising response rate.

J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH

Johnson & Johnson’s (NYSE: JNJ) Imbruvica is poised to beat Roche’s top selling drug in the chronic lymphocytic leukemia drugs market over the next few years. This can be attributed to expected competition for Rituxan from biosimilars, given its market exclusivity period ended last year.

Can Johnson & Johnson’s Imbruvica Sales Beat Roche’s Rituxan In Chronic Lymphocytic Leukemia Market By 2021?

Amgen

FDA gives nod to Amgen's (AMGN) Avsola (ABP 710), a biosimilar of J&J's blockbuster rheumatoid arthritis drug, Remicade.

Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar

Innovative Industrial Properties

Intuitive Surgical

A holding period of forever sounds perfect for these top-tier businesses.

3 Healthcare Stocks to Buy and Never Sell

Anthem

UnitedHealth Group

According to the Aggregated Portfolio, a GuruFocus Premium feature, the four broadest-owned stocks within the health care sector are UnitedHealth Group Inc.

4 Health Care Stocks Gurus Broadly Own

Bank of America

Chevron

Danaher

Duke Energy

McDonald's

Microsoft

PayPal

Under Armour

Walmart

The best stocks for young investors include household names like Johnson & Johnson, Unilever and Chevron. Are you building your portfolio?

10 Stocks That Should Be Every Young Investor’s First Choice

Here we discuss the ups and downs of J&J's (JNJ) stock this year.

J&J Stock Witnesses Volatility in '19: What to Expect in 2020

JNJ stock topped a buy point. But several lawsuits claiming Johnson & Johnson baby powder caused cancer are weighing on shares.

New Tests Find No Asbestos In J&J Baby Powder — Is JNJ Stock A Safe Buy?

JNJ stock popped Wednesday after the Dow Jones pharmaceutical company said additional testing found no asbestos in its baby powder. Independent laboratories performed 155 additional tests.

JNJ Stock Rallies As New Testing Rules Out Asbestos In Baby Powder

Johnson & Johnson blamed the feds for a recent asbestos scare as the company cleared its signature baby powder of the toxic substance. The pharmaceutical giant said “test sample contamination and/or analyst error” most likely led a US Food and Drug Administration contractor to find tiny amounts of asbestos in samples of Johnson’s Baby Powder,.

Johnson & Johnson blames FDA for baby powder asbestos scare

J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.

J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders

Johnson & Johnson said on Tuesday that more tests showed that Johnson's Baby Powder was free of asbestos after U.S. Food and Drug Administration investigations had found trace amounts of the material.

Johnson & Johnson confirms no asbestos in Johnson's Baby Powder

Johnson & Johnson  said on Tuesday that more tests showed that Johnson's Baby Powder was free of asbestos after U.S. Food and Drug Administration investigations had found trace amounts of the material.

Johnson & Johnson confirms no asbestos in Johnson's Baby Powder.

Johnson & Johnson’s(NYSE:JNJ) Stelara could become the #2 drug in the Crohn’s Disease market over the next few years. Crohn’s Disease causes inflammation of the digestive tract.

Can Johnson & Johnson’s Stelara Become Number 2 Drug In Crohn’s Disease Market?

Johnson & Johnson stock is grinding out a long-term breakout pattern despite the endless flow of legal developments.

Johnson & Johnson Stock Shaking Off Legal Headwinds

Abbott Labs

Which stock wins in a matchup between these two healthcare giants?

Better Buy: Abbott Laboratories vs. Johnson & Johnson

AmerisourceBergen

Amneal Pharmaceuticals

Endo International

McKesson

Mallinckrodt PLC

Teva Pharmaceutical

Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.

News for Johnson & Johnson Stock (JNJ)